| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. |
| 掲載誌名 | 正式名：Breast cancer (Tokyo, Japan) 略 称：Breast Cancer ISSNコード：18804233/13406868 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print |
| 著者・共著者 | Kazutaka Narui, Kana Miyahara, Yukari Uemura, Akimitsu Yamada, Kazuhiro Araki, Fumie Fujisawa, Takahiro Nakayama, Takashi Ishikawa, Hirohito Seki, Kimito Yamada, Masahiro Kitada, Takayuki Iwamoto, Naruto Taira, Yuichiro Kikawa, Tomohiko Aihara, Hirofumi Mukai |
| 発行年月 | 2026/07 |
| 概要 | BACKGROUND:Cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy are the standard first- and second-line treatments for hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). In clinical practice, however, CDK4/6 inhibitors are also used in patients previously treated with chemotherapy, but their efficacy and safety in this setting remain unclear.PATIENTS AND METHODS:We conducted a multi-institutional prospective cohort study to obtain real-world evidence regarding the clinical efficacy and safety of combination therapy with abemaciclib and endocrine therapy in chemotherapy-treated patients with HR+/HER2- MBC.RESULTS:Between December 2019 and November 2022, 181 patients were registered. The median progression-free survival (PFS) and overall survival periods for abemaciclib were 10.3 months and 25.2 months, respectively. The median number of endocrine therapies for MBC was one regimen. The median PFS period of the patients treated with abemaciclib as maintenance therapy after chemotherapy was 13.8 months. The median PFS period of patients with prior treatment history with CDK4/6 inhibitor (palbociclib) was 6.6 months. Patients with one or two chemotherapy regimens in the previous line had a significantly longer PFS period than those with three or more regimens. Regarding safety, severe adverse events were observed; these were consistent with known abemaciclib profile.CONCLUSION:Abemaciclib with endocrine therapy demonstrates considerable efficacy and manageable safety in chemotherapy-treated HR+/HER2-MBC. Notably, the > 1-year PFS observed when used as maintenance therapy, in the absence of disease progression, underscores its potential clinical utility. |
| DOI | 10.1007/s12282-026-01889-6 |
| PMID | 42406276 |